These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37854158)

  • 1. The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer.
    Ashok Kumar P; Basnet A
    Transl Lung Cancer Res; 2023 Sep; 12(9):1838-1841. PubMed ID: 37854158
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
    Matsuzawa R; Morise M; Kinoshita F; Tanaka I; Koyama J; Kimura T; Kondoh Y; Tanaka T; Shima K; Hase T; Wakahara K; Ishii M; Hashimoto N
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3885-3893. PubMed ID: 36006483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic assessment of C‑reactive protein and neutrophil to lymphocyte ratio in patients with non-small cell lung cancer.
    Zhao T
    Wien Klin Wochenschr; 2022 Oct; 134(19-20):705-711. PubMed ID: 35794490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the role of colonic and other anatomical sites uptake by [
    Rizzo A; Cantale O; Mogavero A; Garetto L; Racca M; Venesio T; Anpalakhan S; Novello S; Gregorc V; Banna GL
    Thorac Cancer; 2023 Aug; 14(24):2473-2483. PubMed ID: 37442801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
    Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Wei Y; Xu J; Huang X; Xie S; Lin P; Wang C; Guo Y; Zou S; Zhao Z; Wen W; Song Y; Bao Z; Zhang L; Liu W; Kong W; Wang W; He B; Zhang S; Zhou C; Chen Y; Yu Z
    J Thorac Dis; 2023 Apr; 15(4):1892-1900. PubMed ID: 37197527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer.
    Drpa G; Sutic M; Baranasic J; Jakopovic M; Samarzija M; Kukulj S; Knezevic J
    Radiol Oncol; 2020 Sep; 54(4):437-446. PubMed ID: 32960780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
    Minami S; Ihara S; Ikuta S; Komuta K
    World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
    Inomata M; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Ichikawa T; Imanishi S; Yamada T; Miwa T; Hayashi R; Tobe K
    Pathol Oncol Res; 2020 Jan; 26(1):327-333. PubMed ID: 30232703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Liu B; Kotenko S; Li W
    Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
    Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
    Front Oncol; 2021; 11():690093. PubMed ID: 34150659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
    Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
    Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.